Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable.
We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state.
We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | Investigation of Coagulation Parameters in Hereditary Haemorrhagic |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients with HHT and normal controls
Exclusion Criteria:
- Previous thrombosis, recent ill health
Contacts and Locations| United Kingdom | |
| Imperial College Hammersmith Campus | |
| London, United Kingdom, W12 0NN | |
| Principal Investigator: | Claire Shovlin | Imperial College London |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00230659 History of Changes |
| Other Study ID Numbers: | IC/CLS6 |
| Study First Received: | September 29, 2005 |
| Last Updated: | September 29, 2005 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Additional relevant MeSH terms:
|
Telangiectasia, Hereditary Hemorrhagic Telangiectasis Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Hemorrhagic Disorders Hematologic Diseases Vascular Malformations Cardiovascular Abnormalities Congenital Abnormalities |
ClinicalTrials.gov processed this record on May 23, 2013